Health TrialsbyHealthPanel

Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment

ConditionsAttention Deficit Hyperactivity Disorder (ADHD)Substance-related Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs) is a highly common comorbid condition associated with serious medical and psychosocial consequences. However, and despite the international consensus recommending integrated treatment for this comorbidity, few studies tested the efficacy of specific psychotherapeutic treatment for this comorbidity.

The aim of this study is to test the efficacy of a specific group Cognitive and Behavioral Therapy (CBT) for the treatment of adults with this comorbidity.

This is a longitudinal, randomized controlled intervention study utilizing a crossover design between the intervention and treatment-as-usual (TAU) waitlist condition, aimed at testing the effectiveness of an integrated psychotherapeutic group treatment for adults with comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 or older ;

Suffer from at least one moderate to severe SUD regarding the DSM-5 (tobacco excluded) ;

Being currently treated for a SUD by a physician of a psychologist ;

Being diagnosed with an ADHD according to the DIVA 2.0 of DIVA-5 ;

Disqualifiers

Age under 18;

Pregnant or breastfeeding women;

Not having sign the consent form;

Major difficulties in understanding and/or expressing themselves in french;

Trial design

Design model

Crossover

Treatments tested in this trial

  • TAU+integrated group CBT

    Other intervention

    TAU+integrated group CBT : participants receive a group psychotherapeutic intervention of Integrated CBT lasting eight weekly two-hour sessions, in parallel with their usual individual care. The sessions are led by a psychologist trained and certified in the practice of CBT and a psychiatrist specialized in addiction medicine. The psychotherapeutic intervention follows a fixed structure and is inspired by the CBT manual for the management of ADHD associated with SUDs published by Matthys et al. (2018). This intervention includes modules on planning and organization, time and distraction management, emotional regulation, work on impulsive behaviors and social skills, cognitive work, as well as substance use management and relapse prevention. The sessions will be punctuated by regular breaks to ensure participants' comfort and the integration of the skills worked on during the sessions. TAU : participants receive their usual care, in exception of group psychotherapeutic interventions.

Treatment groups

132 Participants
are divided into 2 treatment groups
Group A: Treatment-WaitingOther 1 intervention
Group B: Waiting-TreatmentOther 1 intervention

Trial outcomes

Primary outcomes

1

Emotion dysregulation

Emotion dysregulation subscale of the Adult Self Report Scale for ADHD ( ASRS-31). The scale score ranges from 0 (low dysregulation) to 16 (high dysregulation).

Time frame
Week 1 ; Week 9 ; Week 18 ; Week 31

Secondary outcomes

1

Substance use

Description: Frequency and quantity of substance in the last 15 days, assessed with the Timeline Follow-Back Questionnaire (TLFB)

Time frame
Week 1 ; Week 9 ; Week 18 ; Week 31
2

Self-confidence in abstinence

Description: Self-confidence in the capacity to not use substance in several tempting contexts, assessed with the Brief Situational Confidence Questionnaire (BSCQ). The scale score ranges from 0% (low self-confidence) to 16 (high self-confidence).

Time frame
Week 1 ; Week 9 ; Week 18 ; Week 31
3

Craving

Craving frequency and intensity measured with the Craving Experience Questionnaire (CEQ).The frequency scale ranges from 11 (very infrequent) to 110 (always) and the intensity scale ranges from 11 (low) to 110 (extreme).

Time frame
Week 1 ; Week 9 ; Week 18
4

Nicotine dependence

Nicotine dependence assessed with the Heaviness of Smoking Index (HSI).The total score ranges from 0 (no dependence) to 6 (severe dependence).

Time frame
Week 1 ; Week 9 ; Week 18 ; Week 31

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Source ClinicalTrials.gov
Apply now